CD8A and melanoma: For instance, in patients with melanoma, NSCLC, and bladder cancer, the expression of multiple immune checkpoints by neoantigen-specific CD4+ T cells and CD8+ T cells was linked to non-responsiveness to the combination of treatment with the neoantigen vaccine and PD1 checkpoint blockade [33].